{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "29786110",
  "DateCompleted": {
    "Year": "2018",
    "Month": "10",
    "Day": "15"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "04",
    "Day": "08"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2018",
        "Month": "05",
        "Day": "17"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.3892/ijmm.2018.3689"
    ],
    "Journal": {
      "ISSN": "1791-244X",
      "JournalIssue": {
        "Volume": "42",
        "Issue": "2",
        "PubDate": {
          "Year": "2018",
          "Month": "Aug"
        }
      },
      "Title": "International journal of molecular medicine",
      "ISOAbbreviation": "Int J Mol Med"
    },
    "ArticleTitle": "Multi\u2011layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/\u03b2\u2011catenin signaling activation (Review).",
    "Pagination": {
      "StartPage": "713",
      "EndPage": "725",
      "MedlinePgn": "713-725"
    },
    "Abstract": {
      "AbstractText": [
        "\u03b2\u2011catenin/CTNNB1 is an intracellular scaffold protein that interacts with adhesion molecules (E\u2011cadherin/CDH1, N\u2011cadherin/CDH2, VE\u2011cadherin/CDH5 and \u03b1\u2011catenins), transmembrane\u2011type mucins (MUC1/CD227 and MUC16/CA125), signaling regulators (APC, AXIN1, AXIN2 and NHERF1/EBP50) and epigenetic or transcriptional regulators (BCL9, BCL9L, CREBBP/CBP, EP300/p300, FOXM1, MED12, SMARCA4/BRG1 and TCF/LEF). Gain\u2011of\u2011function CTTNB1 mutations are detected in bladder cancer, colorectal cancer, gastric cancer, liver cancer, lung cancer, pancreatic cancer, prostate cancer and uterine cancer, whereas loss\u2011of\u2011function CTNNB1 mutations are also detected in human cancer. ABCB1, ALDH1A1, ASCL2, ATF3, AXIN2, BAMBI, CCND1, CD44, CLDN1, CTLA4, DKK1, EDN1, EOMES, FGF18, FGF20, FZD7, IL10, JAG1, LEF1, LGR5, MITF, MSX1, MYC, NEUROD1, NKD1, NODAL, NOTCH2, NOTUM, NRCAM, OPN, PAX3, PPARD, PTGS2, RNF43, SNAI1, SP5, TCF7, TERT, TNFRSF19, VEGFA and ZNRF3 are representative \u03b2\u2011catenin target genes. \u03b2\u2011catenin signaling is involved in myofibroblast activation and subsequent pulmonary fibrosis, in addition to other types of fibrosis. \u03b2\u2011catenin and NF\u2011\u03baB signaling activation are involved in field cancerization in the stomach associated with Helicobacter\u00a0pylori (H.\u00a0pylori) infection and in the liver associated with hepatitis C virus (HCV) infection and other etiologies. \u03b2\u2011catenin\u2011targeted therapeutics are functionally classified into \u03b2\u2011catenin inhibitors targeting upstream regulators (AZ1366, ETC\u2011159, G007\u2011LK, GNF6231, ipafricept, NVP\u2011TNKS656, rosmantuzumab, vantictumab, WNT\u2011C59, WNT974 and XAV939), \u03b2\u2011catenin inhibitors targeting protein\u2011protein interactions (CGP049090, CWP232228, E7386, ICG\u2011001, LF3 and PRI\u2011724), \u03b2\u2011catenin inhibitors targeting epigenetic regulators (PKF118\u2011310), \u03b2\u2011catenin inhibitors targeting mediator complexes (CCT251545 and cortistatin A) and \u03b2\u2011catenin inhibitors targeting transmembrane\u2011type transcriptional outputs, including CD44v6, FZD7 and LGR5. Eradicating H.\u00a0pylori and HCV is the optimal approach for the first\u2011line prevention of gastric cancer and hepatocellular carcinoma (HCC), respectively. However, \u03b2\u2011catenin inhibitors may be applicable for the prevention of organ fibrosis, second\u2011line HCC prevention and treating \u03b2\u2011catenin\u2011driven cancer. The multi\u2011layered prevention and treatment strategy of \u03b2\u2011catenin\u2011related human diseases is necessary for the practice of personalized medicine and implementation of precision medicine."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Omics Network, National Cancer Center, Chuo Ward, Tokyo 104\u20110045, Japan."
          }
        ],
        "LastName": "Katoh",
        "ForeName": "Masaru",
        "Initials": "M"
      }
    ],
    "GrantList": [
      {
        "GrantID": "U19 AI135964",
        "Acronym": "AI",
        "Agency": "NIAID NIH HHS",
        "Country": "United States"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Greece",
    "MedlineTA": "Int J Mol Med",
    "NlmUniqueID": "9810955",
    "ISSNLinking": "1107-3756"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "beta Catenin"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Animals"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Chronic Disease"
    },
    {
      "QualifierName": [
        "methods"
      ],
      "DescriptorName": "Drug Discovery"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Epigenesis, Genetic"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Fibrosis"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "drug therapy",
        "genetics",
        "metabolism",
        "pathology"
      ],
      "DescriptorName": "Inflammation"
    },
    {
      "QualifierName": [
        "methods"
      ],
      "DescriptorName": "Molecular Targeted Therapy"
    },
    {
      "QualifierName": [
        "drug therapy",
        "genetics",
        "metabolism",
        "pathology"
      ],
      "DescriptorName": "Neoplasms"
    },
    {
      "QualifierName": [
        "methods"
      ],
      "DescriptorName": "Precision Medicine"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Protein Interaction Maps"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Wnt Signaling Pathway"
    },
    {
      "QualifierName": [
        "antagonists & inhibitors",
        "metabolism"
      ],
      "DescriptorName": "beta Catenin"
    }
  ]
}